Rifamycin Antibiotics
The rifamycin class includes rifampin (rifampicin), rifabutin, rifapentine, rifaximin, and the parent compound rifamycin SV. 1
Clinically Available Rifamycins
First-Line Tuberculosis Agents
Rifampin (Rifampicin): The most widely used rifamycin and cornerstone of TB treatment, administered at 10 mg/kg daily (maximum 600 mg). It is the most potent CYP450 inducer among rifamycins, causing extensive drug interactions 2, 1.
Rifabutin: Reserved for patients with unacceptable drug interactions with rifampin (particularly those on antiretroviral therapy) or rifampin intolerance. Dosed at 5 mg/kg daily (maximum 300 mg), it has substantially less CYP450 induction activity than rifampin 2, 3, 1.
Rifapentine: Has a longer half-life (>14 hours) permitting once-weekly administration in selected patients during continuation phase TB treatment. It has intermediate CYP450 induction activity between rifampin and rifabutin 2, 4, 1.
Gastrointestinal-Specific Agent
- Rifaximin: Used exclusively for gastrointestinal disorders including hepatic encephalopathy, irritable bowel syndrome, and travelers' diarrhea. It is not systemically absorbed on oral dosing, remaining confined to the GI tract where it achieves high local concentrations 5.
Parent Compound
- Rifamycin SV: The original rifamycin compound with demonstrated anti-inflammatory and immunomodulatory properties, though rarely used clinically today 6.
Key Clinical Distinctions
Drug interaction profiles differ substantially among rifamycins, which is critical for managing patients on complex medication regimens. Rifampin causes the most extensive drug interactions through potent CYP450 induction, reducing serum concentrations of protease inhibitors, NNRTIs, oral contraceptives, warfarin, methadone, and numerous cardiovascular and immunosuppressive agents 2, 7. Rifabutin permits safer coadministration with many antiretroviral agents, though dose adjustments are required (150 mg two or three times weekly with ritonavir; 450-600 mg daily with efavirenz) 2, 8, 7.
All rifamycins share the common mechanism of inhibiting bacterial RNA polymerase by binding the β-subunit in the RNA exit tunnel, blocking productive RNA formation 5, 9, 10. They exhibit activity against most bacterial genera, with particular efficacy against mycobacteria.
Common Pitfalls
The universal orange discoloration of bodily fluids (sputum, urine, sweat, tears) occurs with all systemic rifamycins and can permanently stain soft contact lenses 2. Patients must be warned at treatment initiation.
Women of reproductive potential on oral contraceptives require barrier contraception methods when taking any rifamycin due to reduced contraceptive efficacy 2, 7.
Rifabutin-specific toxicity includes uveitis (particularly when combined with macrolides), neutropenia, and polyarthralgias, with risk increasing at higher doses 2, 11.